BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix


2/25/2009 8:30:47 AM

Primate trials validate efficacy of the process

THOUSAND OAKS, Calif., Feb. 24 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has successfully completed the initial primate trials validating the efficacy of the proprietary bone growth regeneration UCB-1 (NELL-1) protein in spinal fusion surgery. 100% fusion was obtained in a 3 month period. No cystic lesion was observed. The company is currently preparing Pre-IDE studies.

Bone Biologics has been developing the protein as a Platform Technology since 2004, leveraging the previous ten years of research in the lab performed by the founding scientists at UCLA. This Platform Technology is combined with DBX(R) demineralized bone matrix to promote bone growth in spinal fusion. Results have exhibited rapid bone growth, high quality of bone, and no ectopic bone growth.

The successful primate surgical outcomes used the DBX(R) demineralized bone matrix (scaffold) produced by the Musculoskeletal Transplant Foundation (MTF). "The Musculoskeletal Transplant Foundation is a world leader in tissue research and development, and has been both a financial and strategic partner to Bone Biologics over the past four years," said Bruce A. Hazuka, CEO of Bone Biologics.

"We are very pleased with the progress that Bone Biologics has made in achieving each of their development milestones over the past four years and look forward to their continued progress toward FDA approval and commercialization on the timelines projected by the company," Bruce Stroever, CEO of MTF said.

The platform technology will be subject to the FDA review and approval process, including clinical trials. It is not currently approved for use in humans.

About The Musculoskeletal Transplant Foundation

MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2008, MTF distributed over 400,000 tissue grafts.

About Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space. The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years. The acquisition of an exclusive worldwide license and the financing from MTF was the genesis of the development of this recombinant protein.

CONTACT: Bruce A. Hazuka of Bone Biologics, +1-818-324-2742



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES